Fig 1.
TREND, flow diagram of inclusion.
ICD-10 = International Classification of Diseases and Related Health Problems, ADHD = Attention-deficit/hyperactivity disorder, MPH = Methylphenidate, INDICES = INDIvidualised drug therapy based on pharmacogenetics: focus on carboxylesterase 1, AR = Adverse reaction, SAR = Serious adverse reaction. 1 = Treatment initiated after the study inclusion period was terminated. 2 = Clinician decision of patient’s discontinuation of treatment with MPH due to adverse events, ARs, and SARs.
Table 1.
Characteristics of included and excluded patients at study entry.
Table 2.
Clinical follow-up from week 0 to week 12 (n = 187).
Fig 2.
Examples of graphs for estimations sum scores of inattention, hyperactivity-impulsivity, and adverse reactions throughout the 12 weeks as estimated by the linear mixed models, n = 207.
Clinician rated ADHD-Rating-Scale (ADHD-RS-C); Inattention subscale, 9 items [range 0–27] and Hyperactivity-Impulsivity subscale, 9 items [range 0–27]. Clinician rated Barkley’s Stimulant Side Effect Rating Scale (BSSERS-C), 17 items, [range 0–153]. Explanatory variables: Sex, age (7 to 9 years and 10 to 12 years), functional impairments in week 0, and Clinical Global Impression Severity (CGI-S). CGI-S devided into: 1–3 = Not ill, borderline ill, mildly ill. CGI-S 4 = Moderately ill, CGI-S 5 = Markedly ill. CGI-S 6–7 = Severly ill, among the most extreme ill patients.
Table 3.
Baseline characteristics as predictors for symptom reductions and adverse reactions (n = 207).
Table 4.
Baseline characteristics as predictors for the chance of normalisation or borderline normalisation of the clinician rated ADHD core symptoms score (n = 207).
Table 5.
Baseline characteristics as predictors for end-dose of IR-MPH (n = 187).